Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?
TNF inhibitors
amyotrophic lateral sclerosis
pharmacovigilance
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
01
01
2019
revised:
14
04
2019
accepted:
30
04
2019
pubmed:
7
5
2019
medline:
14
4
2020
entrez:
7
5
2019
Statut:
ppublish
Résumé
TNFα modulation has been reported to be either beneficial or detrimental in amyotrophic lateral sclerosis (ALS) and therefore appears as a key issue. We analysed the relationship between TNFα inhibitor (TNFi) exposure and ALS. We performed descriptive analysis of ALS reports in patients treated with TNFi, registered in the French Pharmacovigilance Database (FPvD) and disproportionality analyses by the 'case'/'non-case' method in FPvD and worldwide database (Vigibase
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-694Informations de copyright
© 2019 Société Française de Pharmacologie et de Thérapeutique.
Références
Brown R.H., Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. (2017) 377 162-172.
Loustau V., Foltz V., Poulain C., Rozenberg S., Bruneteau G. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFα blockers for ankylosing spondylitis: fortuitus association or new side effect of TNFα blockers? Joint Bone Spine (2009) 76 213-214.
Khalid S.I., Ampie L., Kelly R., Ladha S.S., Dardis C. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front. Neurol. (2017) 8 11.
Rothman K.J., Lanes S., Sacks S.T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. (2004) 13 519-523.
Saliba L., Moulis G., Abou Taam M. et al. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam. Clin. Pharmacol. (2016) 30 162-171.
Bougea A., Anagnostou E., Stamboulis E., Kararizou E. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. Rev. Neurol. (Paris) (2014) 170 228-229.
Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. (2019) 18 211-220.
Osawa Y., Banno Y., Nagaki M. et al. TNF- induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J. Immunol. (2001) 167 173-180.
Yin X., Ren M., Jiang H. et al. Downregulated AEG-1 together with inhibited PI3K/Akt pathway is associated with reduced viability of motor neurons in an ALS model. Mol. Cell Neurosci. (2015) 68 303-313.
Gouel F., Van Do B., Chou M.-L. et al. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways: protective effect of platelet lysate in models of neurodegenerative disease. J. Tissue Eng. Regen. Med. (2017) 11 3236-3240.
Lo S.Z., Steer J.H., Joyce D.A. Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway. Arthritis Res. Ther. (2011) 13 R24.
O’ Reilly E., Tirincsi A., Logue S.E., Szegezdi E. The Janus face of death receptor signaling during tumor immunoediting. Front Immunol. (2016) 7 446.
Golomb B.A., Verden A., Messner A.K., Koslik H.J., Hoffman K.B. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf. (2018) 41 403-413.